Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)
Related Experiment Videos
Juan Manuel Sepúlveda-Sánchez1, Miguel Gil-Gil2, Miriam Alonso-García3
1Medical Oncology Department, Hospital Universitario, 12 de Octubre, Avda. Andalucía s/n, 28041, Madrid, Spain. sepulvedasanchez@seom.org.
Background:
The cell cycle checkpoint G1/S, dependent on cyclin-dependent kinase (CDK) 4 amplification/overexpression and retinoblastoma phosphorylation, is altered in most anaplastic oligodendrogliomas (AOs).
Objective:
We aimed to evaluate the efficacy of palbociclib, an oral inhibitor of CDK4/6 with proven efficacy in breast cancer, in patients with AO. The primary endpoint was progression-free survival at 6 months.
Patients And Methods:
We conducted a multicenter, open-label, phase II trial evaluating the efficacy and safety of palbociclib in patients with AO who progressed on radiotherapy and chemotherapy with histologically and molecularly confirmed grade 3 oligodendroglioma and conserved retinoblastoma protein (pRb) expression by immunohistochemistry. Patients were treated with palbociclib (125 mg/day) for 3/1 weeks on/off.
Results:
Overall, 34 patients were enrolled across 10 hospitals in the Spanish Group of Neuro-Oncology (GEINO) study. The study was stopped early owing to the lack of efficacy, with 74% of evaluable patients progressing within 6 months, which was insufficient to consider palbociclib as an active drug in this population. Within the median follow-up of 12 months, the median progression-free survival was 2.8 months [95% confidence interval (CI) 2.6-3.1] and the median overall survival was 32.1 months (95% CI 5.1-59.2). There were no partial or complete responses; only 13 patients (38%) achieved stable disease as the best response. Palbociclib was well tolerated, with neutropenia (grade 3 or higher: 58.8%) and thrombocytopenia (grade 3 or higher: 14.7%) as the most common adverse events (AEs). Both AEs had no significant impact.
Conclusion:
Despite the good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent AO.
Trial Registration:
This study is registered with ClinicalTrials.gov, identifier NCT0253032 (retrospectively registered on 21 August 2015).
Insights
Palbociclib, a CDK4/6 inhibitor, showed limited efficacy in treating anaplastic oligodendroglioma (AO). Despite good tolerance, the drug did not improve progression-free survival in patients with recurrent AO.
Area of Science:
- Neuro-oncology
- Molecular oncology
- Clinical trials
Background:
- Anaplastic oligodendroglioma (AO) frequently exhibits alterations in the G1/S cell cycle checkpoint, involving cyclin-dependent kinase (CDK) 4 and retinoblastoma protein (pRb).
- CDK4/6 inhibitors like palbociclib have demonstrated efficacy in breast cancer, suggesting potential for other malignancies.
Purpose of the Study:
- To evaluate the efficacy and safety of palbociclib in patients with recurrent anaplastic oligodendroglioma.
- To determine the progression-free survival at 6 months as the primary endpoint.
Main Methods:
- A multicenter, open-label, phase II trial was conducted.
- Patients with histologically and molecularly confirmed grade 3 oligodendroglioma, progression after standard therapy, and conserved pRb expression received palbociclib (125 mg/day, 3 weeks on/1 week off).
Main Results:
- The study enrolled 34 patients and was stopped early due to lack of efficacy; 74% of evaluable patients progressed within 6 months.
- Median progression-free survival was 2.8 months, and median overall survival was 32.1 months. No complete or partial responses were observed; 38% achieved stable disease.
- Palbociclib was well tolerated, with neutropenia and thrombocytopenia being the most common adverse events, having no significant impact on treatment.
Conclusions:
- Palbociclib monotherapy demonstrated unfavorable efficacy in recurrent anaplastic oligodendroglioma.
- Despite good tolerability, palbociclib is not recommended as a treatment for this patient population based on this trial's findings.